Clinical Scorecard: Effective VA-ECMO Intervention for Severe Cardiotoxicity Induced by Neoadjuvant Paclitaxel and Cisplatin in Laryngeal Cancer: A Case Study

At a Glance

Key Highlights

• Paclitaxel and cisplatin combination chemotherapy can rarely cause severe cardiotoxicity including fulminant myocarditis and high-grade atrioventricular block.
• VA-ECMO provides lifesaving temporary mechanical circulatory support in refractory cardiogenic shock secondary to chemotherapy-induced cardiotoxicity.
• Early recognition and prompt initiation of VA-ECMO can lead to successful recovery in severe cardiotoxicity cases unresponsive to conventional therapies.

Guideline-Based Recommendations

Diagnosis

• Monitor cardiac biomarkers (e.g., high-sensitivity troponin I) and ECG for early detection of cardiotoxicity during chemotherapy.
• Use echocardiography to assess left and right ventricular function and exclude other causes such as obstructive coronary disease.
• Consider coronary angiography to rule out ischemic causes in acute cardiogenic shock with elevated cardiac enzymes.

Management

• Initiate supportive care including vasopressors, mechanical ventilation, and renal replacement therapy as indicated.
• Implant temporary pacemaker for high-grade atrioventricular block.
• Promptly initiate VA-ECMO in refractory cardiogenic shock unresponsive to medical management.

Monitoring & Follow-up

• Continuous hemodynamic and rhythm monitoring in intensive care setting.
• Serial echocardiography to evaluate myocardial recovery.
• Laboratory monitoring of cardiac biomarkers, renal and liver function, and electrolytes.

Risks

• Potential for severe cardiotoxicity including fulminant myocarditis and conduction abnormalities with paclitaxel and cisplatin chemotherapy.
• Risk of multi-organ dysfunction secondary to cardiogenic shock.
• Complications related to VA-ECMO including bleeding, infection, and thrombosis.

Patient & Prescribing Data

Adult patients with locally advanced laryngeal cancer receiving neoadjuvant paclitaxel and cisplatin chemotherapy

Although cardiotoxicity is rare, clinicians should be vigilant for severe cardiac complications; VA-ECMO can be a critical rescue therapy in refractory cardiogenic shock.

Clinical Best Practices

• Perform baseline cardiac evaluation including ECG and echocardiography before initiating TP chemotherapy.
• Maintain high suspicion for cardiotoxicity in patients presenting with chest pain, dyspnea, or arrhythmias during or after chemotherapy.
• Rapidly escalate care to advanced mechanical support such as VA-ECMO when conventional therapies fail to stabilize cardiogenic shock.
• Multidisciplinary management involving oncology, cardiology, and critical care teams is essential for optimal outcomes.

References

• Neoadjuvant chemotherapy in laryngeal cancer
• Cardiotoxicity of paclitaxel and cisplatin
• VA-ECMO in cardiogenic shock